Purpose
|
JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
|
Characteristics
|
Tradename: Serdemetan Target: p53 activator, E3 ligase inhibitor, Mdm2 inhibitor Receptor: p53,HDM2,Mdm2 Status: INN
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
97?% +
|
Formula
|
C21H20N4
|
Solubility
|
200 mM in DMSO
|